(Regulatory) views on Biomarker defined Subgroups

Similar documents
The update of the multiplicity guideline

Biomarkers in oncology drug development

Safeguarding public health Subgroup analyses scene setting from the EU regulators perspective

confirmatory clinical trials - The PMDA Perspective -

Basket Trials: Features, Examples, and Challenges

Accelerating Innovation in Statistical Design

Design and analysis of clinical trials

The Rapidly Changing World of EGFR Mutation-Positive Acquired Resistance

EGFR inhibitors in NSCLC

The Roles of Short Term Endpoints in. Clinical Trial Planning and Design

VeriStrat Poor Patients Show Encouraging Overall Survival and Progression Free Survival Signal; Confirmatory Phase 2 Study Planned by Year-End

IRESSA (Gefitinib) The Journey. Anne De Bock Portfolio Leader, Oncology/Infection European Regulatory Affairs AstraZeneca

Targeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center

Regulatory Aspects - AML & CLL

Overview of requirements for surrogate endpoint adoption by CHMP: a regulatory perspective. Dr Beatriz Flores CDDF- October 2017

Effective Implementation of Bayesian Adaptive Randomization in Early Phase Clinical Development. Pantelis Vlachos.

Supplemental Table S2: Subgroup analysis for IL-6 with BMI in 3 groups

Patient Selection: The Search for Immunotherapy Biomarkers

Design considerations for Phase II trials incorporating biomarkers

Live WebEx meeting agenda

Safeguarding public health CHMP's view on multiplicity; through assessment, advice and guidelines

Reflection paper on assessment of cardiovascular risk of medicinal products for the treatment of cardiovascular and metabolic diseases Draft

Is there a Cookbook for Oncology Clinical Trials?

Statistics for Clinical Trials: Basics of Phase III Trial Design

Changing demographics of smoking and its effects during therapy

Safeguarding public health Subgroup Analyses: Important, Infuriating and Intractable

Reflection paper on assessment of cardiovascular safety profile of medicinal products

Decision Making in Confirmatory Multipopulation Tailoring Trials

PROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC. Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy

Only In Few Cases Have Subgroups Been Defined in Advance With Formal Analysis

Exploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)

EGFR MUTATIONS: EGFR PATHWAY AND SELECTION OF FIRST-LINE THERAPY WITH TYROSINE KINASE INHIBITORS

Predictive biomarker enrichment designs in Phase II clinical trials

Clinical Trial Design to Expedite Drug Development Mary W. Redman, Ph.D.

Statistical Considerations for Novel Trial Designs: Biomarkers, Umbrellas and Baskets

Bayesian additive decision trees of biomarker by treatment interactions for predictive biomarkers detection and subgroup identification

Regulatory Considerations in Oncology Trials in China. Jiang, Frank, MD, PhD VP, Asia Pacific R&D, Sanofi

Biomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007

Design for Targeted Therapies: Statistical Considerations

Lecture Outline. Biost 590: Statistical Consulting. Stages of Scientific Studies. Scientific Method

Designs for Basket Clinical Trials and the Exploratory/Confirmatory Paradigm

EMEA experience with endpoints for Oncology drug approval

P values From Statistical Design to Analyses to Publication in the Age of Multiplicity

Regulatory Challenges in Reviewing Oncology Product Applications

Basket and Umbrella Trial Designs in Oncology

pan-canadian Oncology Drug Review Final Clinical Guidance Report Nivolumab (Opdivo) for Non-Small Cell Lung Cancer June 3, 2016

Research Approach & Design. Awatif Alam MBBS, Msc (Toronto),ABCM Professor Community Medicine Vice Provost Girls Section

Confirmatory subgroup analysis: Multiple testing approaches. Alex Dmitrienko Center for Statistics in Drug Development, Quintiles

PKPD modelling to optimize dose-escalation trials in Oncology

Noninferiority Clinical Trials

EGFR Mutation-Positive Acquired Resistance: Dominance of T790M

On the Utility of Subgroup Analyses in Confirmatory Clinical Trials

Possibilities and risks associated with directly moving from Phase I to Phase III: Adaptive designs and Co

Meta-Analysis. Zifei Liu. Biological and Agricultural Engineering

NSCLC: immunotherapy as a first-line treatment. Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To)

Cancer du sein métastatique et amélioration de la survie Pr. X. Pivot

Confounding and Interaction

Treatment of EGFR mutant advanced NSCLC

Delivering on the Promise of Personalised Healthcare

Panitumumab: The KRAS Story. Chrissie Fletcher, MSc. BSc. CStat. CSci. Director Biostatistics, Amgen Ltd

How to use prior knowledge and still give new data a chance?

EU regulatory concerns about missing data: Issues of interpretation and considerations for addressing the problem. Prof. Dr.

July, ArQule, Inc.

CLINICAL PROTOCOL DEVELOPMENT

pan-canadian Oncology Drug Review Initial Clinical Guidance Report Nivolumab (Opdivo) for Non-Small Cell Lung Cancer April 1, 2016

Media Release. Basel, 26 March 2018

A response by Servier to the Statement of Reasons provided by NICE

Selection and estimation in exploratory subgroup analyses a proposal

SAWP BMWP GTWP. Other WPs SWP QWP BWP CHMP BPWP. PhVWP VWP CTWP EWP

Clinical Trials in the Era of Personalised Medicine and Biomarkers. Chris Karapetis New Zealand Society of Oncology Conference 2 nd July 2012

Use of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies. Eric H. Rubin, MD Merck Research Laboratories

DRAFT (Final) Concept Paper On choosing appropriate estimands and defining sensitivity analyses in confirmatory clinical trials

Lead team presentation:

Non-inferiority: Issues for today and developments for tomorrow. Kevin Carroll AstraZeneca

Population Enrichment Designs Case Study of a Large Multinational Trial

Experimental Design. Terminology. Chusak Okascharoen, MD, PhD September 19 th, Experimental study Clinical trial Randomized controlled trial

Greg Pond Ph.D., P.Stat.

Planning Sample Size for Randomized Evaluations.

Adjusting the Crossover Effect in Overall Survival Analysis Using a Rank Preserving Structural Failure Time Model: The Case of Sunitinib GIST Trial

Industry Perspective: Minimal (Measurable) Residual Disease in Chronic Lymphocytic Leukemia

Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective

La metodologia della ricerca clinica: aspetti salienti per l oncologo

95% 2.5% 2.5% +2SD 95% of data will 95% be within of data will 1.96 be within standard deviations 1.96 of sample mean

Immunotherapy and Targeted Therapies: The new face of cancer treatment

Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?

Jan Bogaerts Scientific Director EORTC Headquarters Belgium

Concepts and Case Study Template for Surrogate Endpoints Workshop. Lisa M. McShane, Ph.D. Biometric Research Program National Cancer Institute

Bayesian Methods in Regulatory Science

Looking Beyond the Standard-of- Care : The Clinical Trial Option

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) POINTS TO CONSIDER ON MISSING DATA

Slide 1. Slide 2 Maintenance Therapy Options. Slide 3. Maintenance Therapy in the Management of Non-Small Cell Lung Cancer. Maintenance Chemotherapy

Overview of Biomarker Development for Immune PD-1/L1 Checkpoint Blockade

Metastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian

The Need for Adaptive Trials for Simultaneous Determination of Efficacy of a Therapeutic and a Diagnostic. Eric H. Rubin Merck

Innovative Analytic Approaches in the Context of a Global Pediatric IBD Drug Development

Janet E. Dancey NCIC CTG NEW INVESTIGATOR CLINICAL TRIALS COURSE. August 9-12, 2011 Donald Gordon Centre, Queen s University, Kingston, Ontario

Big data vs. the individual liver from a regulatory perspective


Accelerating Phase II-III Oncology Drug Development Through the Use of Adaptive Designs

Background Comparative effectiveness of nivolumab

Transcription:

(Regulatory) views on Biomarker defined Subgroups Norbert Benda Disclaimer: Views expressed in this presentation are the author's personal views and not necessarily the views of BfArM

Biomarker defined subgroups Using (genetic) biomarkers to define subgroups of patients with improved efficacy improved tolerability improved benefit/risk Stratification according to biomarker defined patient characteristics stratified medicine = precision medicine Biomarker to select patients that are likely to respond to treatment Biomarker as a surrogate to measure response to treatment N Benda Regulatory Issues in Stratified Medicine 23 June 2016 Page 2

Personalized/individualized/stratified medicine Unique therapies e.g. implants using rapid prototyping, (stem) cell therapy complex /expensive therapies impeding large clinical trials Stratification according to specific patient characteristics e.g. biomarker defined subpopulation Individualized regimen dose adjustment by age/weight/renal function individual dose titration etc. N Benda Regulatory Issues in Stratified Medicine 23 June 2016 Page 3

Stratified therapies: Examples Cetuximab treatment of colorectal cancer in patients with wild-type K-ras mutation Trastuzumab treatment of HER-2-positive breast cancer Gefitinib treatment of NSCLC in patients with EGFR mutation N Benda Regulatory Issues in Stratified Medicine 23 June 2016 Page 4

Stratified therapies Example: Gefitinib (IRESSA) IPASS Study: Gefitinib vs Paclitaxel PFS ORR OS BM+: HR = 0.482, 95% ci (0.362; 0.642) BM-: HR = 2.853, 95% ci (2.048; 3.975) BM+: OR = 2.751, 95% ci (1.646; 4.596) BM-: OR = 0.036, 95% ci (0.005; 0.273) BM+: HR = 0.776, 95% ci (0.500; 1.202) BM-: HR = 1.384, 95% ci (0.915; 2.092) N Benda Regulatory Issues in Stratified Medicine 23 June 2016 Page 5

Biomarker used for stratified therapies Conventional development: looking for a safe and effective treatment in a given population/indication Stratified medicine looking for a treatment and a population where this treatment is safe and effective given a broader population: looking for a subgroup in which benefit is more favorable than in the complementary group = Looking for positive treatment x subgroup interaction = Looking for a treatment and a predictive biomarker Development: Exploration and confirmation N Benda Regulatory Issues in Stratified Medicine 23 June 2016 Page 6

Research project on biomarker defined populations University Medical Centre Göttingen BfArM (2016-2019) 1. empirical investigation of evidence on subgroup effects 2. comparing exploratory statistical methods for subgroup identification 3. method assessment based on regulatory criteria 4. method development modelling between-study heterogeneity 5. assessment of regulatory consequences of between-study heterogeneity 6. combining exploratory and confirmatory subgroup identification in clinical development using adaptive enrichment designs and basket trials. 7. updated comprehensive biomarker classification 8. systematic assessment of European SmPCs and the FDA drug labels N Benda Regulatory Issues in Stratified Medicine 23 June 2016 Page 7

Stratified therapies: Exploration Looking for most promising interaction predictive biomarker (BM) inconsistency between subgroups in-vitro / clinical randomize-all studies Positive interaction re. efficacy tolerability Questions/issues optimized strategy may consider multiple biomarkers repeatability of the diagnostic tool / adjudication process interaction may relate to a surrogate endpoint relevant interaction size positive interaction in efficacy but negative interaction in tolerability? N Benda Regulatory Issues in Stratified Medicine 23 June 2016 Page 8

Stratified therapies Treatment x subgroup interaction implies treatment x subject interaction treatment effect varies across subject may be difficult to verify w/o within-subject comparison/cross-over interaction tests w.r.t. subgroups often lack power S. Senn (Mastering variation: variance components and personalised medicine, SiM 2015): Thus, I am not claiming that elements of individual response can hardly ever be identified. I am claiming that the effort necessary, whether in design or analysis, is rarely made.. In short, the business of personalising medicine is likely to be difficult. We already know that it has turned out to be much more difficult than many thought it would be. N Benda Regulatory Issues in Stratified Medicine 23 June 2016 Page 9

Any subject-by-treatment interaction? Differentiate Setting 1 Setting 2 individual subjects Subpopulation 1 Subpopulation 2 observing response C = 0 response A = 1 N Benda Regulatory Issues in Stratified Medicine 23 June 2016 Page 10

Any subject-by-treatment interaction? Or? Setting 3 population Subpopulation 1 Subpopulation 2 e.g. 50% always respond to A and C 40% always respond to A 10% always respond to none between subject variability vs within subject variability N Benda Regulatory Issues in Stratified Medicine 23 June 2016 Page 11

Any subject-by-treatment interaction? Observe Setting 1 Subpopulation 1 Subpopulation 2 covariate (biomarker) < c lots of biomarker options: chance finding? biomarker > c N Benda Regulatory Issues in Stratified Medicine 23 June 2016 Page 12

Stratified therapies: Exploration Success may relate to multiple biomarker Example: Rosuvastatin cardiovascular disease prevention stratification according to hs-crp (high sensitive C-reactive protein) LDL cholesterol risk ratio in low-ldl subjects RR = 0.88 (low hs-crp) RR = 0.47 (high hs-crp) risk ratio in high-ldl subjects RR = 0.42 (low hs-crp) RR = 0.72 (high hs-crp) N Benda Regulatory Issues in Stratified Medicine 23 June 2016 Page 13

Stratified therapies: Confirmation Regulatory requirement confirm efficacy in subgroup (BM+) in an independent Phase III trial with proper type-1 error control show positive benefit risk in BM+ plausibility for a reduced efficacy in BM Study design options study in BM+ only (some) other data in BM needed stratification in BM+ and BM adaptive design that decides at interim for BM+ or all N Benda Regulatory Issues in Stratified Medicine 23 June 2016 Page 14

Stratified therapies: Confirmation Study in BM + only Issues population size information on BM Population size weaker requirements depending on medical need increased model assumptions / type-1 error Information on BM usefulness of the biomarker justification to exclude BM usually no confirmatory proof of effect irrelevance in BM N Benda Regulatory Issues in Stratified Medicine 23 June 2016 Page 15

Stratified therapies: Confirmation Adaptive design to decide on BM+ Interim analysis to decide on subgroup or all fully pre-specified BM subgroup two null hypotheses no effect in all no effect in BM + multiplicity adjustment required p-value combination test allows for free decision rule decision rule may use external information Bayesian rules could be applied (e.g. Brannath et al SiM 2009) some information on BM generated usefulness of the biomarker N Benda Regulatory Issues in Stratified Medicine 23 June 2016 Page 16

Stratified therapies: Confirmation Possible adaptive designs Predefined subgroup to be decided on at interim no subgroup definition or refinement at interim to limit the number of hypotheses to be tested use of all data with adequate multiplicity adjustment Adaptive signature design adjust for full population vs (any) subpopulation if full population is unsuccessful use first stage to define subpopulation use second stage to confirm Biomarker adaptive threshold design Adjust for full population vs biomarker defined subpopulation with any threshold b of biomarker score B If full population is unsuccessful use resampling methods to analyse Z* = max{z(b)} for test statistic Z N Benda Regulatory Issues in Stratified Medicine 23 June 2016 Page 17

Stratified therapies: Confirmation Stratified design BM + and BM - Full information on different effect sizes usefulness of biomarker tested exclusion or inclusion of BM justified Borrowing strength from BM safety may be concluded from total population biological plausibility required efficacy may be extrapolated based on covariates but difficult to justify when fundamental difference assumed N Benda Regulatory Issues in Stratified Medicine 23 June 2016 Page 18

Role of subgroups in pivotal trials in general Internal consistency assessing homogeneity or heterogeneity evaluating interaction subgroup x treatment Predefined confirmatory subgroup analysis designed to assess efficacy in subgroup Exclusion of subgroups in successful trials optimizing the study population N Benda Regulatory Issues in Stratified Medicine 23 June 2016 Page 19

Stratified therapies: Issues Assessment of interaction / different effect sizes interaction test less informative lack of power scale dependency in general, descriptive assessment scale dependency: equal treatment effects on risk difference means different effect sizes on odds ratios and vice versa decision on multiplicative or additive model may not be well justified N Benda Regulatory Issues in Stratified Medicine 23 June 2016 Page 20

Stratified therapies: Issues Issues in stratified design Potential selection bias of treatment effect when deciding on BM+ or all adaptive design alleviates selection bias Success in BM+ but no clear interaction exclusion of BM - may not be informative and may be challenged proof of irrelevance in BM would require large sample sizes N Benda Regulatory Issues in Stratified Medicine 23 June 2016 Page 21

Summary (1) Biomarker defined subgroups Stratified therapies main focus of the current discussion based on predictive biomarkers requires the identification of relevant interaction biomarker/subgroup x therapy repeatability of the adjudication process paramount may not be restricted to one biomarker only discrimination procedures related to multiple biomarkers could be optimized N Benda Regulatory Issues in Stratified Medicine 23 June 2016 Page 22

Summary (2) Promise of stratified therapies depends on size of the interaction further restriction appears less promising residual variability limits the precision of precision medicine In general more evidence required to support selection generally weak evidence on the usefulness of the selection blurred by different sources of variability Confirmatory strategies based on pivotal study in subgroup only adaptive design to decide on subgroup or all stratified design borrowing information from BM to be further justified e.g. similar safety profile? N Benda Regulatory Issues in Stratified Medicine 23 June 2016 Page 23